Tricuspid Regurgitation Clinical Trials 2023

What are the top hospitals conducting tricuspid regurgitation research?

When it comes to cutting-edge clinical trials in the field of tricuspid regurgitation, several top hospitals across the United States are leading the way. In Rochester, Minnesota, Mayo Clinic takes precedence with five ongoing trials focused on this condition and an impressive track record of eight completed studies. Their commitment to investigating tricuspid regurgitation dates back to 2010 when they recorded their first trial. Meanwhile, on the West Coast, Oregon Health & Science University in Portland has also emerged as a prominent institution for tricuspid regurgitation research. Currently conducting five active trials and having conducted six all-time studies since their inaugural trial in 2018.

In Atlanta's Piedmont Heart Institute, four active clinical trials are currently underway examining new approaches to treating tricuspid regurgitation. Their expertise in this area is evident by their history of five previously conducted investigations since initiating their first trial just a few years ago in 2018. Likewise, Northwestern University in Chicago stands out with its own set of four ongoing clinical trials focused on tricuspid regurgitation while contributing valuable knowledge through a total of five past studies dating back only three years and commencing from 2018.

Last but not least is Morristown Medical Center located in Morristown where they too have been actively involved at forefront handling four current cases under investigation pertaining Triscupid Regugutation.Taking forward similar dedication over these few recent years seen carrying successful six scientific experiments so far that started around 2015 which solidifies theirs standing amid significant contributors within this medical frontier nationwide.

These prestigious hospitals symbolize hope for those grappling with tricuspid regurgitation and underline healthcare professionals' unwavering efforts across various locations throughout the country. Through these pioneering clinical trials aimed at better understanding and treating this condition affecting heart valves' functionality; we move closer towards enhancing patient outcomes while making strides toward improved cardiac health treatment options globally

Which are the best cities for tricuspid regurgitation clinical trials?

When it comes to tricuspid regurgitation clinical trials, several cities in the United States offer significant research opportunities. New york leads the way with 17 active studies focusing on treatments like the Edwards EVOQUE System and PASCAL System. Atlanta follows closely behind with 11 ongoing trials investigating similar interventions. Houston and Los Angeles also contribute to the field with their respective studies on transcatheter tricuspid valve replacement and repair systems. Finally, Rochester offers valuable insights into severe tricuspid regurgitation due to atrial fibrillation and other related conditions through seven active trials. These cities provide vital platforms for advancing knowledge and potential breakthroughs in treating tricuspid regurgitation.

Which are the top treatments for tricuspid regurgitation being explored in clinical trials?

When it comes to exploring new treatments for tricuspid regurgitation in clinical trials, one standout option is transcatheter tricuspid valve replacement. This innovative procedure has shown promise and is currently being tested in two active trials specifically focused on tricuspid regurgitation. Since its introduction in 2020, it has already become a topic of interest with three all-time trials dedicated to this condition. As researchers delve deeper into the potential benefits of transcatheter tricuspid valve replacement, there is hope that it could offer a much-needed solution for patients suffering from tricuspid regurgitation.

What are the most recent clinical trials for tricuspid regurgitation?

Exciting advancements are being made in the field of tricuspid regurgitation, with recent clinical trials offering promising possibilities. One such trial focuses on the VDyne System Treatment Arm, which aims to address tricuspid regurgitation through a phase 1 study. Another significant trial investigated the effectiveness of heterotopic implantation using the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava for treating tricuspid regurgitation. While this particular trial became available back in 2015, it remains highly relevant and provides valuable insights into potential treatment options for patients facing tricuspid regurgitation. With ongoing research and innovation, there is hope for improved outcomes and quality of life for those affected by this condition.

What tricuspid regurgitation clinical trials were recently completed?

Recently completed clinical trials have made significant strides in the field of tricuspid regurgitation. One such trial was conducted by Abbott Laboratories and concluded in September 2021, evaluating a novel treatment approach for this condition. Additionally, Medtronic sponsored a trial that investigated the effectiveness of their device in managing tricuspid regurgitation, which reached completion in January 2021. These advancements are encouraging and offer potential breakthroughs for patients with tricuspid regurgitation, highlighting ongoing efforts to improve treatment options for this cardiac condition.